Anti-Survivin antibodies, human

Anti-Survivin antibodies, human

Clone: REA459 | Dilution: 1:50
Clone REA459 recognizes the human survivin antigen, a member of the inhibitor of apoptosis (IAP) family. Survivin is also known as baculoviral IAP repeat-containing protein 5 (BIRC5) or apoptosis inhibitor 4 (API4). The survivin protein inhibits caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. Expression of survivin is highly regulated by the cell cycle and is only expressed in the G2-M phase. Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. It is expressed highly in most human tumors and fetal tissue, but is completely absent in terminally differentiated cells. Its overexpression has been demonstrated in breast and lung cancer, prostate, gastric, colon, bladder and esophageal carcinomas, osteosarcomas, and lymphomas. Overexpression of survivin was also found to be significantly associated with a poor prognosis and decreased survival rates in oral, breast, and colorectal cancers.
Additional information: Clone REA459 displays negligible binding to Fc receptors.

Alternative Names

BIRC5, API4, EPR-1, IAP4

Technical specifications

  • Antigen: Survivin
  • Clone: REA459
  • Isotype: recombinant human IgG1
  • Isotype control: REA Control (I) antibodies
  • Alternative names of antigen: BIRC5, API4, EPR-1, IAP4
  • Entrez Gene ID: 332
  • Molecular mass of antigen [kDa]: 16
  • Distribution of antigen: breast cancer cells, lung cancer cells, prostate cancer cells, bladder, colon, other
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Fixation: The antibody is suited for staining of formaldehyde-fixed cells.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: PE
  • Selected References

    1. Fukuda, S. et al. (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 5(5): 1087-1098
    2. Ambrosini, G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3(8): 917-921
    3. Cheung, C. H. et al. (2013) Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther 16(6): 1453-1462
Product options: 2

Product information

Size
Order no.
Price

Anti-Survivin-PE, human

  • REA459
  • 1:50
  • For research use only
for 30
tests
(1)
130-119-139
EUR 116,00 

Anti-Survivin-PE, human

  • REA459
  • 1:50
  • For research use only
for 100
tests
(1)
130-118-962
EUR 302,00